Nom du produit:2-amino-3-hydroxy-3-(4-methoxyphenyl)propanoic acid
IUPAC Name:2-amino-3-hydroxy-3-(4-methoxyphenyl)propanoic acid
- CAS：50897-30-8
- Formule moléculaire：C10H13NO4
- Pureté：95%
- Numéro de catalogue：CM652981
- Poids moléculaire：211.22
| Unité d'emballage |
Stock disponible |
Prix($) |
Quantité |
Pour une utilisation en R&D uniquement..
Détails du produit
- N° CAS:50897-30-8
- Formule moléculaire:C10H13NO4
- Point de fusion:-
- Code SMILES:COC1=CC=C(C=C1)C(O)C(N)C(O)=O
- Densité:
- Numéro de catalogue:CM652981
- Poids moléculaire:211.22
- Point d'ébullition:
- N° Mdl:MFCD09998363
- Stockage:
Category Infos
- Benzenes
- Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.
Column Infos
- Zetomipzomib
- Kezar Life Sciences announces clinical hold of Zetomipzomib IND for treatment of lupus nephritis(LN). Zetomipzomib (KZR-616) is a selective inhibitor of the immunoproteasome currently undergoing clinical investigation in autoimmune disorders.
LN is a disease comprising a spectrum of vascular, glomerular and tubulointerstitial lesions and develops in approximately 50% of SLE patients within 10 years of their initial diagnosis. LN is associated with considerable morbidity, including an increased risk of end-stage renal disease requiring dialysis or renal transplantation and an increased risk of death. There are limited approved therapies for the treatment of LN. Management typically consists of induction therapy to achieve remission and long-term maintenance therapy to prevent relapse.
Recherche 
+86 21 5895 0110 
